Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
TNF Pharmaceuticals ( (TNFA) ) just unveiled an update.
On September 4, 2025, TNF Pharmaceuticals announced the closing of a $7 million private placement financing of convertible preferred stock with its largest strategic stockholder and other existing stockholders. This financing, priced at a 44% premium to market, aims to support the company’s development milestones for its newly licensed light-based computing accelerator technology for blockchain. The company also completed transactions involving the issuance of Series H and Series I Convertible Preferred Stock and amended the terms of its Series F and Series F-1 Convertible Preferred Stock, extending their maturity dates and removing amortization payments.
More about TNF Pharmaceuticals
TNF Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of innovative technologies and pharmaceutical candidates. The company is involved in the advancement of isomyosamine and Supera-CBD, and is exploring strategic opportunities to enhance shareholder value.
Average Trading Volume: 598,039
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.73M
See more insights into TNFA stock on TipRanks’ Stock Analysis page.